+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hematologic Malignancies Testing Market - Global Forecast 2026-2032- Product Image
Hematologic Malignancies Testing Market - Global Forecast 2026-2032- Product Image
New

Hematologic Malignancies Testing Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 186 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5924675
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The hematologic malignancies testing market is rapidly reshaping clinical and laboratory operations as new diagnostics respond to increasingly complex medical requirements. Senior decision-makers now face intersecting challenges around technology innovation, regulatory compliance, and tightening operational margins, all of which demand forward-thinking laboratory and procurement strategies.

Market Snapshot: Hematologic Malignancies Testing Market Growth Trajectory

The global hematologic malignancies testing market is demonstrating robust expansion, rising from USD 6.38 billion in 2025 to USD 7.10 billion in 2026. Projections indicate continued momentum with a compound annual growth rate (CAGR) of 13.29%, positioning the market to reach a value of USD 15.28 billion by 2032. This growth is powered by sustained demand for advanced hematologic diagnostics, accelerated technological adoption, evolving reimbursement standards, and a broadening focus on integrated patient care across major global regions.

Scope & Segmentation of the Hematologic Malignancies Testing Market

  • Technology Types: Molecular diagnostics, immunophenotyping, cytogenetics, next-generation sequencing (NGS), polymerase chain reaction (PCR), flow cytometry, immunohistochemistry, and automated informatics platforms play pivotal roles in enhancing diagnostic sensitivity and laboratory efficiency.
  • Applications: The market addresses diverse clinical imperatives, including disease stratification, early detection, minimal residual disease monitoring, therapy selection, prognostic evaluation, and varying test modalities (laboratory-based and point-of-care) to accommodate patient and provider needs.
  • Sample Types: Blood, bone marrow, and tissue-based specimens constitute the core sample spectrum, each with dedicated processing protocols, varying sensitivity thresholds, and tailored workflow requirements.
  • End User Profiles: Academic and research institutes, hospitals and clinics, centralized reference laboratories, and regional diagnostic centers all utilize hematologic malignancies testing to support clinical decision-making and research advancement.
  • Geographic Coverage: Americas, Europe, Middle East & Africa, and Asia-Pacific regions are characterized by distinct policy frameworks, clinical infrastructures, and supplier landscapes, shaping how diagnostics are accessed and implemented regionally.

Primary Keyword Focus: Hematologic Malignancies Testing Market

Key Takeaways for Senior Decision-Makers

  • Laboratories are combining molecular and immunophenotypic data to deliver actionable, longitudinal insights, supporting precision medicine approaches in hematologic cancer management.
  • Adoption of automation, informatics, and multi-modal assay platforms is increasing, streamlining workflows and ensuring reporting consistency across varied laboratory environments.
  • Point-of-care and decentralized testing capabilities continue to expand, providing faster diagnostic turnaround for clinical teams while centralized laboratories remain essential for high-complexity analyses.
  • Procurement and supply chain leaders are re-evaluating sourcing and partnership models, promoting diversification and dual-sourcing to reduce exposure to global trade shocks and sustain business operations.
  • Collaborative partnerships between assay developers, instrument manufacturers, and pharmaceutical companies are expediting clinical validation and enabling the integration of companion diagnostics for improved patient outcomes.

Tariff Impact: Strategic Response to 2025 U.S. Trade Adjustments

The introduction of U.S. tariffs in 2025 is intensifying cost pressures and adding operational complexity, particularly in the sourcing of reagents and diagnostic instruments. Laboratories and manufacturers are responding strategically by diversifying suppliers, increasing reliance on local sources, renegotiating procurement agreements, and investing in modular instrument architectures. These strategies are designed to safeguard diagnostic service continuity while optimizing total cost of ownership amid fluctuating trade environments.

Methodology & Data Sources

The analysis of the hematologic malignancies testing market employs a mixed-methods research approach. It synthesizes comprehensive literature review with targeted interviews involving laboratory leaders, molecular pathologists, administrators, and industry executives. All findings undergo strict triangulation and peer review to ensure the highest standards of accuracy and data reliability.

Why This Report Matters

  • Provides a strategic framework for portfolio and procurement decisions tailored to both current and emerging needs in hematologic malignancies diagnostics.
  • Clarifies regional adoption patterns and highlights operational strategies that strengthen resilience and scalability for laboratory leaders and supply chain teams.
  • Offers actionable recommendations for organizations and partners seeking to optimize clinical, diagnostic, and operational performance amid evolving market conditions.

Conclusion

The hematologic malignancies testing market continues to evolve with advancements in diagnostics, operational demands, and shifting global dynamics. Organizations prioritizing adaptability in technology and supply chain strategy, coupled with strong clinical collaboration, will be poised to achieve sustained value and deliver improved patient care outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Hematologic Malignancies Testing Market, by Technology
8.1. Cytogenetics
8.1.1. Fluorescence In Situ Hybridization
8.1.2. Karyotyping
8.2. Flow Cytometry
8.3. Immunohistochemistry
8.3.1. Liquid Based
8.3.2. Tissue Based
8.4. Molecular Diagnostics
8.4.1. Fluorescence In Situ Hybridization
8.4.2. Next Generation Sequencing
8.4.3. Polymerase Chain Reaction
9. Hematologic Malignancies Testing Market, by Sample Type
9.1. Blood
9.2. Bone Marrow
10. Hematologic Malignancies Testing Market, by Test Mode
10.1. Laboratory Based
10.2. Point Of Care
11. Hematologic Malignancies Testing Market, by Application
11.1. Leukemia
11.2. Lymphoma
11.3. Multiple Myeloma
11.4. Myelodysplastic Syndromes
12. Hematologic Malignancies Testing Market, by End User
12.1. Academic & Research Institutes
12.2. Hospitals & Clinics
12.3. Reference Laboratories
13. Hematologic Malignancies Testing Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Hematologic Malignancies Testing Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Hematologic Malignancies Testing Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Hematologic Malignancies Testing Market
17. China Hematologic Malignancies Testing Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott Laboratories
18.6. Adaptive Biotechnologies
18.7. Agilent Technologies, Inc.
18.8. Beckman Coulter, Inc.
18.9. Becton, Dickinson and Company
18.10. Bio-Rad Laboratories, Inc.
18.11. F. Hoffmann-La Roche Ltd.
18.12. HORIBA, Ltd.
18.13. ICON PLC
18.14. Illumina, Inc.
18.15. Invitae Corporation
18.16. Invivoscribe, Inc.
18.17. Laboratory Corporation of America Holdings
18.18. Leica Biosystems Nussloch GmbH
18.19. Myriad Genetics, Inc.
18.20. Natera, Inc.
18.21. Nikon Instruments
18.22. Ortho Clinical Diagnostics
18.23. PerkinElmer Corporation
18.24. QIAGEN N.V.
18.25. Siemens AG
18.26. Sysmex Corporation
List of Figures
FIGURE 1. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 115. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 116. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 117. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 118. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 119. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 120. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 121. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 133. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 134. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 135. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 136. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 137. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 138. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 139. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 150. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 152. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 153. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 154. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 155. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 156. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 157. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 158. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 161. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 162. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 163. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 164. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 165. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 166. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 167. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 179. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 180. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 181. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 182. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 183. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 184. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 185. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 186. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 188. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 189. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 190. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 191. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 192. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 193. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 194. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 197. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 198. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 199. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 200. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 201. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 202. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 203. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 204. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 206. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 207. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 208. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 209. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 210. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 211. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 212. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 213. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 214. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 215. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 216. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 217. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 218. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 219. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 220. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
TABLE 221. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 222. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Hematologic Malignancies Testing market report include:
  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • HORIBA, Ltd.
  • ICON PLC
  • Illumina, Inc.
  • Invitae Corporation
  • Invivoscribe, Inc.
  • Laboratory Corporation of America Holdings
  • Leica Biosystems Nussloch GmbH
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Nikon Instruments
  • Ortho Clinical Diagnostics
  • PerkinElmer Corporation
  • QIAGEN N.V.
  • Siemens AG
  • Sysmex Corporation

Table Information

Report AttributeDetails
No. of Pages186
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.1 Billion
Forecasted Market Value ( USD ) by 2032 $ 15.28 Billion
Compound Annual Growth Rate13.2%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Hematologic Malignancies Detection Market Report 2025 - Product Image

Hematologic Malignancies Detection Market Report 2025

  • Report
  • 200 Pages
  • Global
From
CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Europe Hematologic Malignancies Testing Market, By Country, Competition, Forecast and Opportunities, 2020-2030F - Product Image

Europe Hematologic Malignancies Testing Market, By Country, Competition, Forecast and Opportunities, 2020-2030F

  • Report
  • 133 Pages
  • Europe
From
Blastic Plasmacytoid Dendritic Cell Neoplasm Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035 - Product Image

Blastic Plasmacytoid Dendritic Cell Neoplasm Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Europe Hematologic Malignancies Testing Market: Focus on Product, Platform, Disease, End User, and Country - Analysis and Forecast, 2024-2033 - Product Image

Europe Hematologic Malignancies Testing Market: Focus on Product, Platform, Disease, End User, and Country - Analysis and Forecast, 2024-2033

  • Report
  • 100 Pages
  • Europe
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.